Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03971409
Title Avelumab With Binimetinib, Utomilumab, or Anti-OX40 Antibody PF-04518600 in Treating Triple Negative Breast Cancer (InCITe)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Hope Rugo, MD
Indications

triple-receptor negative breast cancer

Therapies

Avelumab + PF-04518600

Avelumab + Utomilumab

Avelumab + Binimetinib

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
University of Alabama at Birmingham Recruiting Birmingham Alabama 35294 United States Details
University of California, San Francisco Recruiting San Francisco California 94143 United States Details
Georgetown University Recruiting Washington District of Columbia 20057 United States Details
Mayo Clinic Not yet recruiting Rochester Minnesota 55905 United States Details
UNC Lineberger Comprehensive Cancer Center Not yet recruiting Chapel Hill North Carolina 27599 United States Details
Vanderbilt University/Ingram Cancer Center Not yet recruiting Nashville Tennessee 37232 United States Details
Baylor College of Medicine Recruiting Houston Texas 77030 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field